Study of AZD2811 + Durvalumab in ES-SCLC
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
31actual
Sites
12
Countries
Poland, South Korea, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-02-23 | actual | When the study began enrolling |
| Primary completion | 2022-06-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-01 | estimated | The whole study's end, after follow-up |
| First posted | 2021-02-09 | actual | When this record first appeared on the registry |
| Results posted | 2025-03-27 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Small-Cell Lung Cancer
Interventions
- Drug: Durvalumab — also filed as Imfinzi
- Drug: AZD2811
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Etoposide
Primary outcome
what the primary-completion date above is the date OFMaintenance Participants Alive and Progression Free (APF12) Per RECIST 1.1 [Efficacy]
measured Up to 12 months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2022-04-21 · 1.5 MB · Prot_000.pdf
Statistical Analysis Planposted 2022-05-05 · 833 KB · SAP_001.pdf
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed